Very proud of my son David Davidson giving a fantastic lecture at the NLA : •Unlocking the Future of Cardiology: The Next Generation of Therapies Driven by Genetic Discovery and my granddaughter Maddie Stevens presenting an original poster on the increases CV risk of having both high Lp(a) and homozygous for 9p21. Three generations of Lipid Researchers at the NLA

Great article about the potential for obicetrapib to prevent Alzheimer's Disease. datadosing.substack.com/p/an…

I was blessed to know and work with Gene Braunwald. His legacy is monumental but on a personal level two lessons stand out. He led the trials that proved the "lower the LDL the better" and later added the word "longer" to lower. Therefore, he helped establish the first principle of preventive Cardiology. He was a refugee from Nazi occupied Austria. Although, I did not know him well enough to discuss his Jewish identity or the recent surge in Anti-Semitism, after October 7th, 2023 I was proud to be one of many to co-sign a letter he drafted expressing his disappointment in the ACC's response to the Hamas atrocities. May the memory of Eugene Braunwald MD, the Father of Modern Cardiology always be a blessing.

I’m honored to be recognized by the @NationalLipid and @foundationofnla with the 2026 Clinician/Educator Award. I’m deeply grateful to the patients, colleagues, and collaborators who make this work possible. Looking forward to the  upcoming #NLASessions.

I am honored and humbled to receive the Foundation of the NLA Clinician/Educator Award. Taking care of patients is my passion and this award is dedicated to my patients that I have been privileged to know over the past 40 years.

My Interview at JPM on BioTech TV x.com/BiotechTV/status/20112…

buzzsprout.com/2508586/episo… Very proud of my former Lipidology Fellow Priya Vishnu. Priya is an accomplished writer and excels in explaining clinical concepts to improve patient care.

Serial CLEERLY scans provide reassurance to a young woman with FH and premature ASCVD that aggressive LDL-c reduction with a statin, ezetimibe and Repatha shows a decrease in non-calcified plaque volume and stabilization of stenoses. Interventional Lipidology is very rewarding!

Lipid Case: 57 yo male with preclinical ASCVD ( LAD lesion 50%) with LDL 57mg/dl but LDL-p 1350 and HDL 51mg/dl and normal HDL-p but no large HDL-p. Genetic test reveals rare apoA1 variant which explains dysfunctional HDL, premature ASCVD and corneal arcus. HDL can matter!

Congratulations to Molly Altenburg MD, the 5th Reyes Prevention Fellow. I was blessed this year with her passion for patient care, enthusiasm for learning Lipidology, outstanding teaching and warm personality. Molly is graduating to lead the Prevention/Lipidology Center at Rush.

Saddened to hear the news of the passing of one of my hero's, Scott Grundy MD PhD. Scott was a pioneer in the burgeoning field of Lipidology, a influential researcher of both nutrition and pharmaceuticals, a great teacher and leader of the national cholesterol guidelines along with my good friend Neil Stone. Scott was also a kind and humble giant. His impact on the prevention of coronary artery disease is unequaled. May his memory be a blessing to all who loved him.

My first patient to start olezarsen ( anti-apoC3 ASO). She is LPL - Heterozygous but also has two ApoA5 SNPs. She has had at least 10 episodes of pancreatitis in the past 2 years and severe eruptive xanthomas despite weekly plasmapheresis. Hoping for a new lease on life!

Excited and proud of the Obicetrapib BROOKLYN trial in patients with HeFH as a late breaker at AHA. Thanks Steve Nicholls for an awesome presentation

My Lipid Legend Podcast on Healio. I enjoy working with my longterm friend Ron Corderio. healio.com/cme/mededtalks/ca…

nytimes.com/2023/07/27/healt… This is the obituary in the NYT of the 117 year old women with the loss of function CETP variant identified in the Bronx Aging Study

Before and after xanthoma regression in a patient with the Lebanese FH mutation. Interventional lipidology works much better than plastic surgery.

Thank you to the hundreds of patients and investigators across ten countries who participated in our Phase 3 BROOKLYN trial. Your support moves us closer to our goal of helping people at risk for cardiovascular disease. bit.ly/4fk9iSn

My first patient with serial CLEERLYs following two years of Repatha. With excellent control of LDL-C and a reduction in Lp(a) there is a marked decrease in non-calcified plaque volume and an increase in calcified plaque. The patient is happy and so is his interventional lipidologist.

The Prevention World lost a giant. George Bakris was the most prolific researcher, teacher and clinician in the history of hypertension. He will live on through his great work. I will remember him most as a great friend and colleague who was always eager to help with his amazing mind. May your memory be a blessing to all your many friends and family.